BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36534151)

  • 1. Risk and predictors of adverse pathology after radical prostatectomy in patients diagnosed with IUSP 1-2 prostate cancer at MRI-targeted biopsy: a multicenter analysis.
    Kesch C; Pantea V; Soeterik T; Marquis A; la Bombarda G; Morlacco A; Barletta F; Radtke JP; Darr C; Preisser F; Zattoni F; Marra G; van den Bergh RCN; Hadaschik B; Gandaglia G;
    World J Urol; 2023 Feb; 41(2):427-434. PubMed ID: 36534151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic resonance imaging target fusion biopsy vs. transrectal ultrasound-guided biopsy - A comparative study of ISUP score upgrading risk in the final radical prostatectomy specimen.
    Guimarães T; Gil M; Medeiros M; Andrade V; Guerra J; Pinheiro H; Fernandes F; Pina J; Lopes Dias J; Campos Pinheiro L
    Arch Ital Urol Androl; 2022 Sep; 94(3):278-284. PubMed ID: 36165470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological findings at radical prostatectomy of biopsy naïve men diagnosed with MRI targeted biopsy alone without concomitant standard systematic sampling.
    Luzzago S; Petralia G; Maresca D; Sabatini I; Cordima G; Brescia A; Verweij F; Garelli G; Mistretta FA; Cioffi A; Pricolo P; Alessi S; Ferro M; Matei DV; Renne G; de Cobelli O; Musi G
    Urol Oncol; 2020 Dec; 38(12):929.e11-929.e19. PubMed ID: 32600928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of systematic, MRI-targeted biopsies alone or in combination for the prediction of unfavourable disease in MRI-positive low-risk prostate cancer patients eligible for active surveillance.
    Ploussard G; Beauval JB; Lesourd M; Almeras C; Assoun J; Aziza R; Gautier JR; Loison G; Portalez D; Salin A; Tollon C; Soulié M; Malavaud B; Roumiguié M
    World J Urol; 2020 Mar; 38(3):663-671. PubMed ID: 31197523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of prostate health index to predict Gleason score upgrading and high-risk prostate cancer in radical prostatectomy specimens.
    Kim H; Jung G; Kim JH; Byun SS; Hong SK
    Sci Rep; 2021 Aug; 11(1):17447. PubMed ID: 34465825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact of Visible Tumor (PI-RADS ≥ 3) on Upgrading and Adverse Pathology at Radical Prostatectomy in Low Risk Prostate Cancer Patients: A Biopsy Core Based Analysis.
    Özkan A; Köseoğlu E; Kılıç M; Baydar DE; Sağlıcan Y; Balbay MD; Canda AE; Kordan Y; Kiremit MC; Çil B; Tuğcu V; Bakır B; Esen T
    Clin Genitourin Cancer; 2022 Feb; 20(1):e61-e67. PubMed ID: 34750082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance and risk factors of International Society of Urological Pathology (ISUP) grade upgrading in prostate cancer patients undergoing robot-assisted radical prostatectomy.
    Takeshima Y; Yamada Y; Teshima T; Fujimura T; Kakutani S; Hakozaki Y; Kimura N; Akiyama Y; Sato Y; Kawai T; Yamada D; Kume H
    BMC Cancer; 2021 May; 21(1):501. PubMed ID: 33947348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological features of Prostate Imaging Reporting and Data System (PI-RADS) 3 MRI lesions in biopsy and radical prostatectomy specimens.
    Rahota RG; Diamand R; Malavaud B; Fiard G; Descotes JL; Peltier A; Beauval JB; Roumeguère T; Roumiguié M; Albisinni S; Ploussard G
    BJU Int; 2022 May; 129(5):621-626. PubMed ID: 34358405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological factors associated with pathological upgrading from biopsy to prostatectomy in patients with ISUP grade group ≤2 prostate cancer.
    Li X; Wang ZX; Zhu YP; Wang J; Yin YS; Zeng XY
    Asian J Androl; 2022; 24(5):487-493. PubMed ID: 35170453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicentric study on accurate grading of prostate cancer with systematic and MRI/US fusion targeted biopsies: comparison with final histopathology after radical prostatectomy.
    Diamand R; Oderda M; Al Hajj Obeid W; Albisinni S; Van Velthoven R; Fasolis G; Simone G; Ferriero M; Roche JB; Piechaud T; Pastore A; Carbone A; Fiard G; Descotes JL; Marra G; Gontero P; Altobelli E; Papalia R; Kumar P; Eldred-Evans D; Giacobbe A; Muto G; Lacetera V; Beatrici V; Roumeguere T; Peltier A
    World J Urol; 2019 Oct; 37(10):2109-2117. PubMed ID: 30652213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of perilesional and multiparametric resonance imaging-targeted biopsies to reduce the risk of upgrading at radical prostatectomy pathology: A retrospective monocentric study.
    Diamand R; Hollans M; Lefebvre Y; Sirtaine N; Limani K; Hawaux E; Abou Zahr R; Mattlet A; Albisinni S; Roumeguère T; Peltier A
    Urol Oncol; 2022 May; 40(5):192.e11-192.e17. PubMed ID: 35236622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the Upgrading Rates of International Society of Urological Pathology Grades and Tumor Laterality in Patients Undergoing Standard 12-Core Prostate Biopsy versus Fusion Prostate Biopsy for Prostate Cancer.
    Demirtaş A; Sönmez G; Tombul ŞT; Demirtaş T; Akgün H
    Urol Int; 2019; 103(3):256-261. PubMed ID: 31242496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of high-grade prostate cancer pattern on MRI-targeted biopsies: predictors for downgrading and importance of concomitant systematic biopsies.
    Manceau C; Fromont-Hankard G; Beauval JB; Lesourd M; Almeras C; Bajeot AS; Gautier JR; Soulié M; Loison G; Salin A; Tollon C; Malavaud B; Roumiguié M; Ploussard G
    World J Urol; 2021 Sep; 39(9):3315-3321. PubMed ID: 33609168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased accuracy of the prostate cancer EAU risk group classification in the era of imaging-guided diagnostic pathway: proposal for a new classification based on MRI-targeted biopsies and early oncologic outcomes after surgery.
    Ploussard G; Manceau C; Beauval JB; Lesourd M; Almeras C; Gautier JR; Loison G; Salin A; Soulié M; Tollon C; Malavaud B; Roumiguié M
    World J Urol; 2020 Oct; 38(10):2493-2500. PubMed ID: 31838560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biparametric Prostate Imaging Reporting and Data System version2 and International Society of Urological Pathology Grade Predict Biochemical Recurrence after Radical Prostatectomy.
    Takeuchi N; Sakamoto S; Nishiyama A; Horikoshi T; Yamada Y; Iizuka J; Maimaiti M; Imamura Y; Kawamura K; Imamoto T; Komiya A; Ikehara Y; Akakura K; Ichikawa T
    Clin Genitourin Cancer; 2018 Aug; 16(4):e817-e829. PubMed ID: 29576444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of adverse pathology at prostatectomy in the era of MRI and targeted biopsies; rethinking active surveillance for intermediate risk prostate cancer patients.
    Bloom JB; Daneshvar MA; Lebastchi AH; Ahdoot M; Gold SA; Hale G; Mehralivand S; Sanford T; Valera V; Wood BJ; Choyke PL; Merino MJ; Turkbey B; Parnes HL; Pinto PA
    Urol Oncol; 2021 Oct; 39(10):729.e1-729.e6. PubMed ID: 33736975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MRI-Fusion Targeted vs. Systematic Prostate Biopsy-How Does the Biopsy Technique Affect Gleason Grade Concordance and Upgrading After Radical Prostatectomy?
    Rührup J; Preisser F; Theißen L; Wenzel M; Roos FC; Becker A; Kluth LA; Bodelle B; Köllermann J; Chun FKH; Mandel P
    Front Surg; 2019; 6():55. PubMed ID: 31620444
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy.
    Gandaglia G; Ploussard G; Valerio M; Marra G; Moschini M; Martini A; Roumiguié M; Fossati N; Stabile A; Beauval JB; Malavaud B; Scuderi S; Barletta F; Afferi L; Rakauskas A; Gontero P; Mattei A; Montorsi F; Briganti A
    Eur Urol Oncol; 2020 Dec; 3(6):739-747. PubMed ID: 32847747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.
    Keefe DT; Schieda N; El Hallani S; Breau RH; Morash C; Robertson SJ; Mai KT; Belanger EC; Flood TA
    Virchows Arch; 2015 Oct; 467(4):437-42. PubMed ID: 26229020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.